EN 中文
Home Strategic Partnerships News Contact us

Strategic Partnerships

IACTA
In July 2020, we entered into a license agreement with IACTA for the license of certain patents and know-how relating to IC-265 and IC-270 in Greater China and certain Southeast Asia countries.
Kato Pharmaceuticals
In September 2016, Zhaoke Pharmaceutical (HK) Limited entered into a license agreement, or the Resolv ER License Agreement, with Kato Pharmaceuticals for an exclusive license of a group of patent rights, or the Kato Patent Rights, and Kato Pharmaceuticals
Visus
In May, 2022, we entered into an exclusive licensing agreement with Visus Therapeutics for the development and commercialization of BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and select Southeast Asian territories.
Vyluma
In October 2020, we entered into a license agreement with Nevakar, which later transferred the agreement to its wholly-owned subsidiary, Vyluma, for an exclusive license to develop, manufacture, register, import and commercialize NVK-002 in Greater China,
RegeneRX
In July 2012, Lee’s Pharm (HK) entered into a license agreement, or the Thymosin 4 License Agreement, with RegeneRx for the license of Thymosin 4 in RGN-259 and any other Thymosin 4-based drug candidates developed by RegeneRx, together, the Thymosin 4-bas
PanOptica
On December 15, 2020, we entered into an exclusive license agreement with PanOptica, Inc. for PAN-90806 (the “PAN-90806 License Agreement”). Under the PAN-90806 License Agreement, PanOptica granted us an exclusive, royalty-bearing, sublicensable license,
NTC
In December 2020, we entered into a license and supply agreement with NTC, and we were granted an exclusive license to develop, import, register, obtain price and seek reimbursement, promote, market, distribute and sell NTC014 in Greater China, South Kore
TOT BIOPHARM.
In January 2017 and April 2020, we entered into a series of product licensing, development and commercialization agreements with TOT BIOPHARM, under which TOT BIOPHARM granted us an exclusive license to commercialize TAB014 for neovascularization-related
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat